Malignant Bowel Obstruction in Platinum-Resistant Ovarian Cancer
A 63-year-old woman with recurrent platinum-resistant high-grade serous ovarian cancer, treated with four prior lines including bevacizumab and a PARP inhibitor, presents with 5 days of vomiting, colicky abdominal pain, and no flatus or stool for 3 days. She has had two prior bowel resections for obstruction. CT shows multiple small-bowel transition points with peritoneal carcinomatosis and no single dominant mass amenable to limited resection. She is dehydrated, nasogastric output is 1.5 L per day, albumin is 2.4 g/dL, and ECOG status is 2. She says she is 'not ready to give up' and wants 'another surgery.' Her daughter is her healthcare proxy and is tearful.
1. Outline your acute management and your assessment of surgical candidacy.
Read the worked answer
Immediate medical management:
- Nothing by mouth, intravenous fluids, and correction of electrolytes and renal function.
- Nasogastric decompression for vomiting and high output.
- Dexamethasone 8-16 mg intravenously daily to reduce peritumoral edema.
- Octreotide 200-300 micrograms subcutaneously every 8 hours, escalating if needed, to reduce gastrointestinal secretions.
- Antiemetics: use ondansetron or haloperidol; avoid metoclopramide in complete obstruction because its prokinetic effect can worsen colic.
- Analgesia: parenteral opioid titrated to comfort; avoid oral agents that cannot be absorbed.
Surgical candidacy: the features against benefit are multiple transition points, carcinomatosis, two prior resections, albumin 2.4, ECOG 2, and a platinum-resistant tumor with limited expected survival. The strongest predictors of surgical benefit are a single obstruction site, absence of ascites, good performance status, and no prior radiotherapy. Her re-obstruction rate would be high and perioperative mortality substantial. A surgical consultation is still appropriate because she is asking for it, but the recommendation should be framed around what surgery can realistically achieve - palliation, not cure or prolonged survival.
2. She and her daughter insist on 'doing something.' How do you structure the conversation and what non-surgical options do you offer?
Read the worked answer
Acknowledge the request rather than opposing it, then make the trade-offs concrete.
- Name the goal: ask what she most wants - to be at home, to stop vomiting, to eat again, to have more time. Her answer should drive the plan.
- Surgery: explain that with multiple blocked segments, an operation would likely mean a stoma, a long recovery, and a substantial chance the obstruction returns within weeks. It is an option, but it is unlikely to deliver what she is hoping for.
- Venting gastrostomy: a percutaneous gastrostomy can decompress the stomach and relieve vomiting, allowing her to be at home without a nasogastric tube; it does not restore eating. This is often the best palliation in multi-level obstruction.
- Continue medical therapy: octreotide and dexamethasone can be continued at home; subcutaneous or intravenous fluids can be given in the community.
- Total parenteral nutrition: generally not indicated in malignant obstruction without a plan for further anticancer treatment; it adds line infections, metabolic complications, and burdens without meaningful benefit.
- Further anticancer therapy: only if she is fit and has a plausible regimen; response takes weeks and will not relieve the current obstruction.
- Hospice and early palliative care: present as an extra layer of support alongside treatment, not as abandonment. Involve the palliative care team now rather than at crisis.
With the daughter as proxy, explore what the patient would have wanted and document the discussion.
3. What is the evidence for octreotide and corticosteroids in malignant bowel obstruction, and how do you decide whether to give further chemotherapy?
Read the worked answer
Octreotide: somatostatin analogues reduce gastrointestinal secretions and thereby vomiting and nasogastric output. The trials are small and mostly single-centre, but the aggregate evidence supports a reduction in secretions and in the need for nasogastric decompression; the effect is greater when combined with a corticosteroid than with either alone. Typical dosing is 300-600 micrograms per day subcutaneously in divided doses, with reduction once symptoms settle. Adverse effects include hyperglycemia and injection-site reactions; it is expensive and access varies.
Corticosteroids: dexamethasone at 4-16 mg daily reduces peritumoral edema and may transiently relieve obstruction. A randomized comparison found the combination of octreotide and dexamethasone superior to either agent alone. Monitor for hyperglycemia, delirium, and insomnia; use the lowest effective dose and plan a taper.
Chemotherapy in obstruction: response in platinum-resistant disease is on the order of 10-20%, and the obstruction will not resolve within the days to weeks needed for a response. It is therefore not a treatment for the obstruction itself. It is reasonable only if she has chemosensitive disease, adequate performance status, and a regimen with a realistic chance of benefit, and if she understands that the obstruction may persist or recur. Otherwise the focus should be symptom control, home-based care, and family support.